Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome
NCT ID: NCT00542295
Last Updated: 2008-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
400 participants
INTERVENTIONAL
2007-07-31
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)
NCT01404923
Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome
NCT00955994
A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)
NCT00394186
Mesalazine Treatment in IBS (The MIBS Study)
NCT01699438
Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide
NCT01678781
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
alverine citrate and simeticone
B
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
alverine citrate and simeticone
placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* with IBS as defined by Rome III criteria
Exclusion Criteria
* Underlying cause for symptomatology, which excludes IBS diagnosis,
* Gastro-intestinal cancer or significant gastro-intestinal surgical background,
* Any acute/uncontrolled systemic pathology
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratoires Mayoly Spindler
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philippe Ducrotte, M.D
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Budapest, , Hungary
Budapest, , Hungary
Budapest, , Hungary
Budapest, , Hungary
Debrecen, , Hungary
Győr, , Hungary
Gyula, , Hungary
Miskolc, , Hungary
Miskolc, , Hungary
Siofolk, , Hungary
Szeged, , Hungary
Székesfehérvár, , Hungary
Bydgoszcz, , Poland
Katowice, , Poland
Oława, , Poland
Szczecin, , Poland
Wroclaw, , Poland
Wroclaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IMTO601
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.